LeMaitre Vascular Reports Strong Q4 2025 Earnings Growth and Strategic Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy LMAT?
Source: seekingalpha
- Significant Sales Growth: LeMaitre Vascular achieved a 16% sales growth in Q4 2025, with a gross margin of 71.7% and a 47% increase in operating income, indicating strong market performance and enhanced profitability.
- International Market Expansion: The company anticipates $10 million in international sales for ArteGraft in 2026, expanding direct operations to Poland as the 32nd country for direct sales, thereby strengthening its competitive position globally.
- Price Strategy Adjustment: LeMaitre announced an 8% blended price increase across its U.S. portfolio, with similar adjustments in Europe, which have been smoothly adopted by hospitals, expected to further boost revenue and profit levels.
- Optimistic Future Outlook: Management projects 2026 revenue of $280 million and adjusted EPS of $2.91, reflecting confidence in future growth despite the impact of a recent cyber incident.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LMAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LMAT
Wall Street analysts forecast LMAT stock price to fall
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 107.395
Low
93.00
Averages
105.20
High
120.00
Current: 107.395
Low
93.00
Averages
105.20
High
120.00
About LMAT
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LeMaitre Vascular to Participate in Five Investor Conferences
- Investor Conference Schedule: LeMaitre Vascular will participate in five investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference on March 10, where management will present at 1:00 PM EDT to enhance the company's visibility among investors.
- Detailed Agenda: Following that, management will present at the Citizens Life Sciences Conference on March 11 at 1:40 PM, and will be available for one-on-one meetings at the Barclays Annual Global Healthcare Conference on March 12, further strengthening investor engagement.
- Virtual Forum Participation: At the KeyBanc Capital Markets Healthcare Forum on March 17, management will present virtually at 3:45 PM, showcasing the company's innovations and market potential in treating peripheral vascular disease.
- ROTH Conference Involvement: LeMaitre will also be available for one-on-one meetings and may participate in a presentation or fireside chat at the 38th Annual ROTH Conference from March 22-24, further expanding communication channels with investors.
See More
LeMaitre Vascular (LMAT.US) Officer Plans to Sell $10.35 Million in Common Stock via Form 144
- Stock Sale Announcement: Officer LeMaitre George intends to sell 100,000 shares of its common stock on February 26.
- Market Value: The total market value of the shares being sold is approximately $10.35 million.
See More
LeMaitre Vascular Reports Strong Q4 2025 Earnings Growth and Strategic Expansion
- Significant Sales Growth: LeMaitre Vascular achieved a 16% sales growth in Q4 2025, with a gross margin of 71.7% and a 47% increase in operating income, indicating strong market performance and enhanced profitability.
- International Market Expansion: The company anticipates $10 million in international sales for ArteGraft in 2026, expanding direct operations to Poland as the 32nd country for direct sales, thereby strengthening its competitive position globally.
- Price Strategy Adjustment: LeMaitre announced an 8% blended price increase across its U.S. portfolio, with similar adjustments in Europe, which have been smoothly adopted by hospitals, expected to further boost revenue and profit levels.
- Optimistic Future Outlook: Management projects 2026 revenue of $280 million and adjusted EPS of $2.91, reflecting confidence in future growth despite the impact of a recent cyber incident.
See More
LeMaitre Vascular Announces 25% Increase in Quarterly Dividend
- Dividend Increase: LeMaitre Vascular has declared a quarterly dividend increase from $0.20 to $0.25 per share, representing a 25% growth, which reflects the company's robust profitability and cash flow, thereby boosting investor confidence.
- Yield Metrics: The forward yield of this dividend stands at 1.09%, indicating the company's commitment to returning value to shareholders while providing an attractive option for income-seeking investors.
- Payment Schedule: The new dividend will be payable on March 26, with a record date of March 12 and an ex-dividend date also set for March 12, ensuring shareholders receive their earnings promptly and reinforcing the relationship between the company and its investors.
- Financial Health: The dividend increase aligns with LeMaitre Vascular's strong financial performance, showcasing the company's competitiveness and sustainability in the market, which is expected to attract more long-term investors' interest.
See More
LeMaitre Vascular to Announce Q4 Earnings on February 25
- Earnings Announcement Date: LeMaitre Vascular is set to release its Q4 earnings on February 25 after market close, with market participants keenly awaiting the results that could influence stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.66, reflecting a 34.7% year-over-year increase, indicating a sustained improvement in the company's profitability that may attract more investor interest.
- Revenue Expectations: The consensus revenue estimate is $62.82 million, representing a 12.7% year-over-year growth, showcasing the company's robust growth in the market and enhancing its competitive position in the medical device industry.
- Performance Review: Over the past year, LeMaitre Vascular has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, demonstrating financial stability and market confidence in its performance.
See More
LeMaitre Vascular Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Announcement: LeMaitre Vascular has announced that it will release its Q4 2025 financial results on February 25, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Schedule: The company plans to hold a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and outlook, aiming to bolster investor confidence in the company's future direction.
- Registration Details: All registrants will receive dial-in information and a PIN to access the live call, reflecting the company's professionalism and convenience in investor relations.
- Industry Context: LeMaitre Vascular focuses on devices and services for peripheral vascular disease, which affects over 200 million people globally, highlighting the company's significance and potential growth in the medical device market.
See More
LeMaitre Vascular to Participate in Five Investor Conferences
- Investor Conference Schedule: LeMaitre Vascular will participate in five investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference on March 10, where management will present at 1:00 PM EDT to enhance the company's visibility among investors.
- Detailed Agenda: Following that, management will present at the Citizens Life Sciences Conference on March 11 at 1:40 PM, and will be available for one-on-one meetings at the Barclays Annual Global Healthcare Conference on March 12, further strengthening investor engagement.
- Virtual Forum Participation: At the KeyBanc Capital Markets Healthcare Forum on March 17, management will present virtually at 3:45 PM, showcasing the company's innovations and market potential in treating peripheral vascular disease.
- ROTH Conference Involvement: LeMaitre will also be available for one-on-one meetings and may participate in a presentation or fireside chat at the 38th Annual ROTH Conference from March 22-24, further expanding communication channels with investors.
See More
LeMaitre Vascular (LMAT.US) Officer Plans to Sell $10.35 Million in Common Stock via Form 144
- Stock Sale Announcement: Officer LeMaitre George intends to sell 100,000 shares of its common stock on February 26.
- Market Value: The total market value of the shares being sold is approximately $10.35 million.
See More
LeMaitre Vascular Reports Strong Q4 2025 Earnings Growth and Strategic Expansion
- Significant Sales Growth: LeMaitre Vascular achieved a 16% sales growth in Q4 2025, with a gross margin of 71.7% and a 47% increase in operating income, indicating strong market performance and enhanced profitability.
- International Market Expansion: The company anticipates $10 million in international sales for ArteGraft in 2026, expanding direct operations to Poland as the 32nd country for direct sales, thereby strengthening its competitive position globally.
- Price Strategy Adjustment: LeMaitre announced an 8% blended price increase across its U.S. portfolio, with similar adjustments in Europe, which have been smoothly adopted by hospitals, expected to further boost revenue and profit levels.
- Optimistic Future Outlook: Management projects 2026 revenue of $280 million and adjusted EPS of $2.91, reflecting confidence in future growth despite the impact of a recent cyber incident.
See More
LeMaitre Vascular Announces 25% Increase in Quarterly Dividend
- Dividend Increase: LeMaitre Vascular has declared a quarterly dividend increase from $0.20 to $0.25 per share, representing a 25% growth, which reflects the company's robust profitability and cash flow, thereby boosting investor confidence.
- Yield Metrics: The forward yield of this dividend stands at 1.09%, indicating the company's commitment to returning value to shareholders while providing an attractive option for income-seeking investors.
- Payment Schedule: The new dividend will be payable on March 26, with a record date of March 12 and an ex-dividend date also set for March 12, ensuring shareholders receive their earnings promptly and reinforcing the relationship between the company and its investors.
- Financial Health: The dividend increase aligns with LeMaitre Vascular's strong financial performance, showcasing the company's competitiveness and sustainability in the market, which is expected to attract more long-term investors' interest.
See More
LeMaitre Vascular to Announce Q4 Earnings on February 25
- Earnings Announcement Date: LeMaitre Vascular is set to release its Q4 earnings on February 25 after market close, with market participants keenly awaiting the results that could influence stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.66, reflecting a 34.7% year-over-year increase, indicating a sustained improvement in the company's profitability that may attract more investor interest.
- Revenue Expectations: The consensus revenue estimate is $62.82 million, representing a 12.7% year-over-year growth, showcasing the company's robust growth in the market and enhancing its competitive position in the medical device industry.
- Performance Review: Over the past year, LeMaitre Vascular has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, demonstrating financial stability and market confidence in its performance.
See More
LeMaitre Vascular Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Announcement: LeMaitre Vascular has announced that it will release its Q4 2025 financial results on February 25, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Schedule: The company plans to hold a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and outlook, aiming to bolster investor confidence in the company's future direction.
- Registration Details: All registrants will receive dial-in information and a PIN to access the live call, reflecting the company's professionalism and convenience in investor relations.
- Industry Context: LeMaitre Vascular focuses on devices and services for peripheral vascular disease, which affects over 200 million people globally, highlighting the company's significance and potential growth in the medical device market.
See More
